首页 | 本学科首页   官方微博 | 高级检索  
相似文献
 共查询到20条相似文献,搜索用时 156 毫秒
1.
Purpose: Wnt pathways control key biological processes that potentially impact on tumor progression and patient survival. The present study analyzed the polymorphism of lipoprotein-related receptor 5 (LRPS) (gene with key functions in Wnt signaling) and its impact on the response to chemotherapy and survival of patients with advanced gastric cancer (AGC). Methods: A total of 107 consecutive patients with AGC treated with first-line chemotherapy of EOF regimen were enrolled in the present retrospective study. The association between single nucleotide polymorphism (SNP) of rs3736228 in LRP5 and the clinical outcomes of the patients was studied. Results: The CC genotype of rs3736228 was significantly correlated with a higher disease control rate when compared to the CT and TT genotypes (89.3% and 61.8%, respectively, P〈0.001). A univariate survival analysis also showed that the progression free survival (PFS) and overall survival (OS) for the patients with the TC and TF genotypes of rs3736228 were worse than for the patients with the CC genotype (PFS: 3.3 and 6.7 months, respectively, HR =0.454, P〈0.001; OS: 8.1 months and 18.8 months, respectively, HR =3.056, P〈0.001). A multivariate Cox model incorporates rs3736228 and clinical features, also identified rs3736228 was significantly associated with the PFS and OS. Conclusions: Our results firstly highlight the importance of LRPY gene of Wnt pathway in the treatment of AGC and identify polymorphism of rs3736228 as independent predictor of disease control rate, PFS and OS in AGC patients treated with first-line chemotherapy of EOF regimen in the Chinese Han population.  相似文献   

2.
Objective: The aim of this study was to determine whether the presence of IL-18 polymorphisms -137 G/C and -607 A/C was associated with grade, clinical stage, and survival in patients with prostate cancer. Methods: The study cohort included 126 patients with prostate cancer. Control group consisted of 125 samples from Chinese population. Genomic DNA was extracted from EDTA-anticoagulated peripheral blood leukocytes by the salting-out method. The genotyping of the two IL-18 polymorphisms was performed using predesigned TaqMan SNP Genotyping Assays. Results: The studied IL-18 gene polymorphisms did not influence susceptibility to prostate cancer in the analyzed group of patients (IL-18-607, P = 0.342; IL-18-137 P = 0.715) but may contribute to disease onset and aggressiveness. IL-18-607 CC genotype was significantly associated with higher tumor grade (P = 0.025) and stage (P = 0.001). IL-18-137 GG genotype was correlated with higher tumor grade (P = 0.018) and stage (P = 0.007). The Cox proportional hazard model showed that tuumor grade and stage grouping were independent prognostic factors but IL-18 polymorphism was not. Polymorphism variants in the IL-18 gene (IL-18-607 and IL-18-137) may be associated with a worse prognosis for prostate cancer. Conclusion: High levels of IL-18 production may play a major role in the growth, invasion and metastasis of prostate cancer.  相似文献   

3.
Objective To analyze the therapeutic efficacy and treatment related toxicities for patients with locally advanced cervical cancer treated with three-dimensional conformal radiotherapy (3DCRT) combined with concurrent chemotherapy. Methods From January 2007 to February 2008, 181 patients with stage ⅡA-ⅣA cervical cancer were retrospectively analyzed. All patients were treated with CT-based three-dimensional external beam and 192Ir intracavity radiotherapy combined with concurrent weekly cisplatin-based chemotherapy. The median age was 50 years (range, 32 to 82 years). The overall survival ( OS), disease-free survival (DFS) and local control (LC) rates were calcalated by Kaplan-Meier method and the difference was compared using Log-rank test. The treatment related toxicities were evaluated according to Radiotherapy Oncology Group (RTOG) criteria. Results With a median follow-up time of 34 months and following rate of 92. 2%, the 3-year OS, DFS and LC rates were 73.4%, 70. 4% and 91.3%,respectively. The 3-year OS rate was 66. 9% for patients with tumor diameter ≥4 cm and 86. 4% for those with tumor diameter <4 cm( χ2 =6. 29 ,P =0. 012). The incidences of grade 1 and grade 2 acute toxicities of the lower gastrointestinal tract and the genitourinary system were 40. 0% ,45.0% and 19. 9% ,4. 4%,retrospectively. There were no grade 3 or more acute toxicities. The incidence of grades 3 or 4 late toxicities of the lower gastrointestinal tract was 4. 9%. Conclusions CT-based three-dimensional external beam and 192Ir intracavity radiotherapy combined with concurrent chemotherapy can achieve good therapeutic effects for locally advanced cervical cancer. The acute and late toxicities are significantly reduced compared with historic controls as a result of incorporation of 3DCRT technique.  相似文献   

4.
Objective: To explore the effects of postmastectomy radiotherapy(PMRT) on the locoregional failure-free survival(LRFFS) and overall survival(OS) of breast cancer patients under different tumor stages and with one to three positive axillary lymph nodes(ALNs). Methods: We conducted a retrospective review of 527 patients with one to three positive lymph nodes who underwent modified radical or partial mastectomy and axillary dissection from January 2000 to December 2002. The patients were divided into the T1-T2 N1 and T3-T4 N1 groups. The effects of PMRT on the LRFFS and OS of these two patient groups were analyzed using SPSS 19.0, Pearson's χ2-test, Kaplan-Meier method, and Cox proportional hazard model. Results: For T1-T2 N1 patients, no statistical significance was observed in the effects of PMRT on LRFFS [hazard ratio(HR)=0.726; 95% confidence interval(CI): 0.233-2.265; P=0.582] and OS(HR=0.914; 95% CI: 0.478-1.745; P=0.784) of the general patients. Extracapsular extension(ECE) and high histological grade were the risk factors for LRFFS and OS with statistical significance in multivariate analysis. Stratification analysis showed that PMRT statistically improved the clinical outcomes in high-risk patients [ECE(+), LRFFS: P=0.026, OS: P=0.007; histological grade III, LRFFS: P〈0.001, OS: P=0.007] but not in low-risk patients [ECE(–), LRFFS: P=0.987, OS: P=0.502; histological grade I-II, LRFFS: P=0.816, OS: P=0.296]. For T3-T4 N1 patients, PMRT effectively improved the local control(HR=0.089; 95% CI: 0.210-0.378; P=0.001) of the general patients, whereas no statistical effect was observed on OS(HR=1.251; 95% CI: 0.597-2.622; P=0.552). Absence of estrogen receptors and progesterone receptors(ER/PR)(–) was an independent risk factor. Further stratification analysis indicated a statistical difference in LRFFS and OS between the high-risk patients with ER/PR(–) receiving PMRT and not receiving PMRT [ER/PR(–), LRFF  相似文献   

5.
Objective To analyze the prognostic factors of patients with leukemia treated with single fraction total body irradiation (SFTBI) followed by hernatopoietic stem cell transplantation (HSCT).Methods From January 2001 to September 2008, 102 patients received HSCT. The differences of the survival rate, relapse rate and incidence of interstitial pneumonia (IP) between groups regarding different genders, ages, pathological types, transplantation methods and TBI parameters were compared and the factors related with the survival rate, relapse rate and incidence of IP were analyzed. Results The followup time ranged from 15 to 1482 days (median, 406 days). The follow-up rate was 95.1%. 86 and 55patients were followed up more than one year and three years. The 1-and 3-year survival rates were 59.0%and 44.0%. In univariate analysis, the 3-year survival rate was signifcantly different between the groups with and without relapse before transplantation (20% vs. 55%, χ2 = 6.33, P = 0. 012), allogeneictranplantation versus autologous tranplantation (39% vs. 68%, χ2 = 8.06, P = 0.005), grade 3 or more acute graft versus host disease (aGVHD) and grade 0 -2 aGVHD (0% vs. 54%, χ2 = 7.52, P = 0.006),with and without relapse after transplantation (19% vs. 58%, χ2 = 10.13, P =0.001), with and without IP (23% vs. 58%, χ2 =8.35, P=0.004). Multivariate analysis showed that grade 3 or more aGVHD was the only statistically significant prognostic factors (χ2 = 12. 74 ,P =0. 000). The l-and 3-year relapse rateswere 30. 0% and 50. 0%. The incidence of relapse was obviously higher in the group with relapse before transplantation than that without (47% vs. 16%, χ2 =7. 32, P=0. 007). Multivariate analysis showed thatrelapse before transplantation was a significant factor predicting relapse after transplantation (χ2 = 9. 39,P =0. 020). The cumulative incidence of IP was 35.0%. The incidence of IP was different between groups with dose homogeneity > 3% and ≤ 3% (27% vs. 4%, χ2 = 5. 21, P = 0. 023), with and without acute parotitis (34% vs. 3%, χ2 = 14. 15, P= 0.000), allogeneic transplantation group and autologous transplantation group (31% vs. 8%, χ2= 7.70, P= 0.006). Multivariate analysis showed that transplantation methods, acute parotitis and dose homogeneity were statistically significant factors in predictingIP (χ2 = 10. 08 , 10. 08 and 7.69 , P = 0. 002 , 0. 002 and 0. 010 , respectively) . Conclusions Patients who develop grade 3 or higher aGVHD have poor prognosis. Dose homogeneity influences the incidence of IP. Patients undergoing allogeneic transplantation are apt to have IP. Acute parotitis is related with IP and might be a predictor.  相似文献   

6.
Objective To investigate the prognosis of patients with nasal NK/T cell lymphoma receiving different treatment modalities. Methods From 1990 to 2004, 85 patients with stage ⅠE and ⅡE primary nasal NK/T cell lymphomas were retrospectively studied. Twenty patients received chemotherapy of CHOP regimen alone, 11 patients received radiotherapy only, 6 patients received radiotherapy followed by more than 2 cycles of chemotherapy, and 48 patients received more than 2 cycles of chemotherapy followed by radiotherapy. Survival analysis was performed by the Kaplan-Meier method, the difference between groups was evaluated by the Log-rank test, and the Cox regression model was used for multivariate analysis. Results The 5-year overall survival rate (OS) was 40%. The 5-year OS was 57% and 28% for limited stage ⅠE and extended stage ⅠE(X2 =8. 87, P =0. 003), and 23% for stage ⅡE, which was similar to extended stage ⅠE (X2 =0. 19, P-0. 664). The 5-year OS was 13%, 54% and 47% for chemotherapy alone, radiotherapy followed with or without chemotherapy, and chemotherapy followed by radiotherapy, respectively. The last two groups had better OS than chemotherapy alone (P = 0. 030 and 0.049). The 5-year OS was 58% and 12% for patients achieving complete response (CR) and uncomplete response (X2 = 30.68, P = 0. 000).The CR rate was 56% and 86% for radiotherapy of ≤50 Gy and >50 Gy (X2 =6.11, P=0. 013). The corresponding 5-year relapse-free survival rate was 89% and 84% (X2 =0.36, P=0.551). Of 68 patients receiving initial chemotherapy, the CR rate of those who received ≤2, 3-4 and ≥5 cycles was 0, 20%and 3 3 % , respectively (X2 = 7.65 , P = 0. 022) . For 5 0 patients who received ≥ 3 cycles of initial chemotherapy and 17 patients who received initial radiotherapy of ≥40 Gy, the CR rate was 28% and 88%(χ2= 18. 75, P= 0. 000). In patients with pathological nodular and ulcer type, the CR rates with radiotherapy were higher than with chemotherapy (100%: 38%, χ2 = 7.92, P = 0. 005; and 100%: 11%,χ2 = 14.40, P = 0. 000). Multivariate analysis showed that stage and recent effect were the independent prognostic factors. Conclusions The initial radiotherapy with 50 Gy is appropriate for early stage nasal NK/T cell lymphomas. Combined chemotherapy could be used for extended stage ⅠE and ⅡE, but the outcome of CHOP regimen is poor.  相似文献   

7.
Objective The benefit of adjuvant chemoradiotherapy remains controversial for gastric cancer patients treated with more than D1 dissection. This retrospective analysis is to distinguish the first site of recurrence in patients treated with curative resection and more than D1 dissection and to find any feasible adjuvant concurrent chemoradiotherapy recommendation for them. Methods All patients treated between January 2002 and December 2004 who met the following criteria were analyzed: primary gastric or gastroesophageal cancer, underwent curative gastrectomy ( UICC R0 ) and more than D1 lymphadenectomy,pathologically staged as T3-4N0-1 M0, or any Tx N2-3M0. There were 297 patients analyzed and 19.5%,52. 2%, 17. 8% , 10. 4% of patients had stage Ⅱ ( T3 N0 M0, T1 N2 M0 ), Ⅲa, Ⅲb and Ⅳ ( M0 ) diseases,respectively. 76. 1% of patients received adjuvant chemotherapy, while Only 2 patients underwent adjuvant radiotherapy. Failure patterns and the prognostic factors for locoregional recurrence were analyzed. Results The median follow-up time was 61 months and the follow-up rate was 92. 3%. 145 patients developed recurrence with a median recurrent time of 26 months. Locoregional recurrence was observed in 82 patients and distant metastasis in 79 patients. Gastric stump, anastomosis, intra-abdominal lymph nodes were the most common sites of locoregional recurrence. Liver and lung were the most frequent sites of distant metastasis. Prognostic variables for locoregional recurrence were identified after univariate analysis,including pathologic type ( χ2 = 11.50, P = 0. 009 ), total number of dissected lymph nodes ( χ2 = 6. 65,P =0. 010), the number of positive lymph node ( χ2 =5. 80,P =0. 016), lymph node capsular invasion ( χ2 =pathologic type, total number of dissected lymph nodes, lymph node capsular invation, AJCC TNM stage and Borrmann type were independent prognostic factors for locoregional recurrence ( χ2 = 6. 77,19. 33,17. 84 and 6. 02,P =0. 009,0. 000,0. 000 and 0. 014). Conclusions Locoregional recurrence remains the main cause of failure for locally advanced gastric or gastroesophageal cancer patients even though the patients have had more than D1 lymphadenectomy. The role of adjuvant concurrent hemoradiotheray for those patients is warranted.  相似文献   

8.
Objective To investigate the prognosis of patients with nasal NK/T cell lymphoma receiving different treatment modalities. Methods From 1990 to 2004, 85 patients with stage ⅠE and ⅡE primary nasal NK/T cell lymphomas were retrospectively studied. Twenty patients received chemotherapy of CHOP regimen alone, 11 patients received radiotherapy only, 6 patients received radiotherapy followed by more than 2 cycles of chemotherapy, and 48 patients received more than 2 cycles of chemotherapy followed by radiotherapy. Survival analysis was performed by the Kaplan-Meier method, the difference between groups was evaluated by the Log-rank test, and the Cox regression model was used for multivariate analysis. Results The 5-year overall survival rate (OS) was 40%. The 5-year OS was 57% and 28% for limited stage ⅠE and extended stage ⅠE(X2 =8. 87, P =0. 003), and 23% for stage ⅡE, which was similar to extended stage ⅠE (X2 =0. 19, P-0. 664). The 5-year OS was 13%, 54% and 47% for chemotherapy alone, radiotherapy followed with or without chemotherapy, and chemotherapy followed by radiotherapy, respectively. The last two groups had better OS than chemotherapy alone (P = 0. 030 and 0.049). The 5-year OS was 58% and 12% for patients achieving complete response (CR) and uncomplete response (X2 = 30.68, P = 0. 000).The CR rate was 56% and 86% for radiotherapy of ≤50 Gy and >50 Gy (X2 =6.11, P=0. 013). The corresponding 5-year relapse-free survival rate was 89% and 84% (X2 =0.36, P=0.551). Of 68 patients receiving initial chemotherapy, the CR rate of those who received ≤2, 3-4 and ≥5 cycles was 0, 20%and 3 3 % , respectively (X2 = 7.65 , P = 0. 022) . For 5 0 patients who received ≥ 3 cycles of initial chemotherapy and 17 patients who received initial radiotherapy of ≥40 Gy, the CR rate was 28% and 88%(χ2= 18. 75, P= 0. 000). In patients with pathological nodular and ulcer type, the CR rates with radiotherapy were higher than with chemotherapy (100%: 38%, χ2 = 7.92, P = 0. 005; and 100%: 11%,χ2 = 14.40, P = 0. 000). Multivariate analysis showed that stage and recent effect were the independent prognostic factors. Conclusions The initial radiotherapy with 50 Gy is appropriate for early stage nasal NK/T cell lymphomas. Combined chemotherapy could be used for extended stage ⅠE and ⅡE, but the outcome of CHOP regimen is poor.  相似文献   

9.
Objective To analyze the prognostic factors of patients with leukemia treated with single fraction total body irradiation (SFTBI) followed by hernatopoietic stem cell transplantation (HSCT).Methods From January 2001 to September 2008, 102 patients received HSCT. The differences of the survival rate, relapse rate and incidence of interstitial pneumonia (IP) between groups regarding different genders, ages, pathological types, transplantation methods and TBI parameters were compared and the factors related with the survival rate, relapse rate and incidence of IP were analyzed. Results The followup time ranged from 15 to 1482 days (median, 406 days). The follow-up rate was 95.1%. 86 and 55patients were followed up more than one year and three years. The 1-and 3-year survival rates were 59.0%and 44.0%. In univariate analysis, the 3-year survival rate was signifcantly different between the groups with and without relapse before transplantation (20% vs. 55%, χ2 = 6.33, P = 0. 012), allogeneictranplantation versus autologous tranplantation (39% vs. 68%, χ2 = 8.06, P = 0.005), grade 3 or more acute graft versus host disease (aGVHD) and grade 0 -2 aGVHD (0% vs. 54%, χ2 = 7.52, P = 0.006),with and without relapse after transplantation (19% vs. 58%, χ2 = 10.13, P =0.001), with and without IP (23% vs. 58%, χ2 =8.35, P=0.004). Multivariate analysis showed that grade 3 or more aGVHD was the only statistically significant prognostic factors (χ2 = 12. 74 ,P =0. 000). The l-and 3-year relapse rateswere 30. 0% and 50. 0%. The incidence of relapse was obviously higher in the group with relapse before transplantation than that without (47% vs. 16%, χ2 =7. 32, P=0. 007). Multivariate analysis showed thatrelapse before transplantation was a significant factor predicting relapse after transplantation (χ2 = 9. 39,P =0. 020). The cumulative incidence of IP was 35.0%. The incidence of IP was different between groups with dose homogeneity > 3% and ≤ 3% (27% vs. 4%, χ2 = 5. 21, P = 0. 023), with and without acute parotitis (34% vs. 3%, χ2 = 14. 15, P= 0.000), allogeneic transplantation group and autologous transplantation group (31% vs. 8%, χ2= 7.70, P= 0.006). Multivariate analysis showed that transplantation methods, acute parotitis and dose homogeneity were statistically significant factors in predictingIP (χ2 = 10. 08 , 10. 08 and 7.69 , P = 0. 002 , 0. 002 and 0. 010 , respectively) . Conclusions Patients who develop grade 3 or higher aGVHD have poor prognosis. Dose homogeneity influences the incidence of IP. Patients undergoing allogeneic transplantation are apt to have IP. Acute parotitis is related with IP and might be a predictor.  相似文献   

10.
Abstract Objective: The aim of the study was to observe the cardiac toxicity caused by different doses of epirubicin in the adjuvant treatment of breast cancer and to evaluate the long-term efficacy. Methods: The 180 cases of breast cancer patients received epirubicin based adjuvant chemotherapy. The patients were randomly assigned to high-dosage group (90 rag/m^2), medium-dosage group (70 mg/m^2) and low-dosage group (50 rag/m^2), the primary endpoint was cardiac toxicity. The secondary outcomes were the 5-year overall survival (OS) and 5-year disease-free survival (DFS). Results: During chemo- therapy, the clinical symptoms such as palpitation, dyspnea and paroxysmal nocturnal dyspnea occurred in 6 patients with the high-dosage group, 4 patients with the medium-dosage group and 3 patients with the low-dosage group. The number of patients who had changed in electrocardiogram (ECG) was 7, 5 and 4 in three groups, respectively. The echocardiographic showed each group had only one case with LVEF 〈 50%, there was no significantly difference (P 〉 0.05). In the three groups, the 5-year DFS rates were 73.3% (44/60) in high-dose group, 53.3% (32/60) in medium-dose group and 41.6% (25/60) in low dose group. The 5-year OS rates were 85.0% (51/60), 68.3% (41/60) and 58.3% (35/60) in three groups, respectively. The differences were statistically significant (P 〈 0.05). Conclusion: The high-dose epirubicin in adjuvant chemotherapy with CEF (cyclophosphamide, epirubicin and fluorouracil) regimen could improve the 5-year OS rate and 5-year DFS rate on patients of breast cancer. The cardiotoxicity was mild-moderate and well tolerated.  相似文献   

11.
吴颖  成芳 《肿瘤防治研究》2020,47(3):190-193
目的比较男性乳腺癌(MBC)与绝经后女性乳腺癌(FBC)患者的预后。方法收集经手术确诊的50例无远处转移MBC患者及512例无远处转移FBC患者的临床病理资料。采用Kaplan-Meier法绘制生存曲线,用Log rank检验分析各曲线之间的差异。采用Cox比例风险分析方法,对有差异的亚类变量进行生存分析。MBC与绝经后的FBC组采用倾向得分匹配及Cox回归分析。结果ER/PR在MBC患者中的表达率高于FBC患者(χ^2=30.651,P=0.000;χ^2=26.909,P=0.000),HER-2阳性表达率较FBC患者低(χ^2=24.274,P=0.000)。单因素分析结果表明,MBC患者的OS与绝经前期FBC患者相似(P=0.268),但与绝经后FBC患者差异有统计学意义(P=0.005);Cox回归显示MBC患者比绝经后FBC患者预后差(P=0.000)。结论与绝经前后的FBC患者相比,MBC患者表现出较高的ER、PR阳性和较低的HER-2阳性表达率,且MBC患者的OS比绝经后FBC患者低。  相似文献   

12.
目的 通过与非妊娠期乳腺癌(non-PABC)比较分析妊娠是否影响妊娠期乳腺癌(PABC)患者的生存。方法 回顾性分析PABC患者资料,对PABC病例按TNM分期、分子分型、发病年龄和诊断时年份与non-PABC病例进行1:2配对。Kaplan-Meier法分析无病生存期(DFS)和总生存期(OS),Log rank检验进行比较。Cox多因素分析评估影响PABC预后的危险因素。结果 PABC组纳入35例患者(妊娠10例;产后一年内25例),non-PABC组纳入70例患者。中位随访时间分别为68.5和70.7月。PABC组5年DFS为51.6%,non-PABC组为72.8%(χ2=4.72, P=0.029);PABC组和non-PABC的5年OS相似(χ2=1.769, P=0.183)。Cox多因素分析显示妊娠是影响PABC患者DFS的独立危险因素(P=0.011)。结论 妊娠期乳腺癌复发风险高,有必要通过进一步研究以便更早期发现妊娠期乳腺癌,并采取干预措施来提高治疗效果。  相似文献   

13.
目的 探讨外周血C反应蛋白与白蛋白比值(C-reactive protein to albumin ratio,CRP/Alb)对P-Gemox方案联合放疗治疗早期结外NK/T细胞淋巴瘤(extranodal NK/T cell lymphoma,ENKTL)患者预后的影响。方法 回顾性分析四川省肿瘤医院2012年至2017年收治的83例ENKTL患者的临床资料。采用X-Tile软件计算CRP/Alb的截断值,根据截断值将患者分为低CRP/Alb组(CRP/Alb<0.4,n=64)和高CRP/Alb组(CRP/Alb≥0.4,n=19),采用Cox回归分析CRP/Alb与预后的关系。结果 低CRP/Alb组患者的3年无进展生存率高于高CRP/Alb组(77.1% vs 30.7%,χ2=20.954,P<0.001),3年总生存率亦高于高CRP/Alb组(87.4% vs 36.1%,χ2=22.559,P<0.001)。多因素Cox回归分析显示,CRP/Alb≥0.4是影响ENKTL患者无进展生存期(HR=4.163,95%CI:1.899~9.128,P<0.001)和总生存期(HR=4.424,95%CI:2.026~9.662,P<0.001)的独立危险因素。低危ENKTL患者和中高危ENKTL患者中,低CRP/Alb组的中位无进展生存期和中位总生存期均高于高CRP/Alb组(P<0.05)。结论 高CRP/Alb的早期ENKTL患者接受P-Gemox方案联合放疗治疗预后较差。  相似文献   

14.
目的 检测真核翻译起始因子5A2(EIF5A2)在肝细胞癌(HCC)中的表达,探讨其与临床病理特征及预后的关系.方法 qRT-PCR和Western blot法分别检测12对新鲜HCC及癌旁非瘤组织中EIF5A2 mRNA和蛋白水平的表达;免疫组织化学检测284对HCC及癌旁非瘤组织中EIF5A2的表达水平,并分析其与...  相似文献   

15.
目的  探讨外周血血小板与淋巴细胞比值(platelet to lymphocyte ratio,PLR)与滤泡淋巴瘤(follicular lymphoma,FL)的预后的关系。方法 回顾性分析四川省肿瘤医院2006年2月至2016年12月收治的74例FL患者的临床资料,通过X-Tile 3.6.1软件计算PLR的截断值,并根据截断值将患者分为低PLR组(<186.8,n=59)和高PLR组(≥186.8, n=15)。采用Cox回归分析PLR与预后的关系。结果 中位随访42个月(范围:6~144个月),4年无疾病进展生存(progression free survival,PFS)为42.0%,4年总生存(overall survival,OS)为54.7%。低PLR组的4年PFS较高PLR组长(51.3% vs 6.7%,χ2=25.320,P<0.001),4年OS亦较高PLR组长(65.7% vs 8.3%,χ2=29.414,P<0.001)。多因素Cox回归分析显示,PLR≥186.8是影响FL患者PFS(HR=3.949,95%CI:1.856~8.404,P<0.001)和OS(HR=4.795,95%CI:2.259~10.178,P<0.001)的独立危险因素。进一步分析发现,在低危FL患者中,低PLR组的中位PFS和中位OS均高于高PLR组(PFS:75.5个月 vs 19.0个月,χ2=14.798,P<0.001;OS:85.5个月 vs 28.0个月,χ2=13.271,P<0.001)。在中高危FL患者中,低PLR组的中位PFS和中位OS亦均高于高PLR组(PFS:32.0个月 vs 12.0个月,χ2=10.766,P=0.001;OS:51.0个月 vs 19.0个月,χ2=13.404,P<0.001)。结论 PLR与FL患者预后相关,LR高的FL患者的预后较差,可作为评估其预后的指标。  相似文献   

16.
目的 探讨3D打印微创导向模板插植放射治疗联合深部热疗治疗局部晚期宫颈癌的近期疗效和不良反应.方法 选取2018年6月至2020年12月于河北省沧州中西医结合医院治疗的80例初治宫颈癌患者,并随机分为联合治疗组及单纯治疗组,每组40例.单纯治疗组外照射采用6 MV?X加速器放疗同步顺铂化疗,后装治疗采用192Ir高剂量...  相似文献   

17.
目的 比较手术和非手术治疗肺腺癌并四肢长骨转移T790M基因突变阳性患者的临床疗效。方法 选择 2016年7月—2018年12月在海南省东方市东方医院、海南省第三人民医院、海南省人民医院以及海南医学院第一附属医院就诊的肺腺癌并四肢长骨转移T790M基因突变阳性患者36例。根据治疗方式分为手术组(n=17)和非手术组(n=19),手术组行肿瘤切除+肢体功能重建术,非手术组行微创(含介入)治疗或放疗,比较两组患者的临床疗效。结果 手术组视觉模拟疼痛评分法(visual analogue scale,VAS)评分下降比例、Ennecking评分增加比例、Kanofsky评分增加比例均高于非手术组(88.2% vs 52.6%,χ2=5.360,P=0.021;82.4% vs 47.4%, χ2=4.760,P=0.029; 70.6%  vs 36.8%,χ2=4.100,P=0.043);手术组和非手术组有效率和疾病控制率差异无统计学意义(52.9% vs 47.4%,χ2=0.111,P=0.738;76.5% vs 78.9%,χ2=0.032,P=0.858);生存分析结果显示,手术组中位生存期高于非手术组(12.0个月vs 9.0个月,χ2=5.009,P=0.024)。结论 手术治疗可缓解T790M基因突变阳性肺腺癌并四肢长骨转移患者的疼痛,改善肢体功能,延长生存期。  相似文献   

18.
目的 分析细胞周期蛋白D1(Cyclin D1)、错配修复蛋白(mis-match repair,MMR)、纤维蛋白原(fibrinogen,FIB)与结肠癌预后的关系。方法 回顾性分析210例结肠癌根治术患者的临床病理资料。采用免疫组化法检测Cyclin D1、MMR的表达,凝固法检测静脉血中FIB的浓度,并分析三者与结肠癌患者术后生存的关系。结果 Cyclin D1低表达的结肠癌患者1年、3年、5年生存率均高于高表达患者(Log-rank χ2=9.878,P=0.002);错配修复基因缺失(mis-match repair genes deletion,dMMR)的患者1年、3年、5年生存率亦较错配修复基因完整(mis-match repair genes complete,pMMR)患者高(Log-rank χ2=5.138,P=0.023);术前FIB正常的患者1年、3年、5年生存率高于FIB异常患者(Log-rank χ2=9.490,P=0.002)。Cyclin D1高表达、FIB异常为结肠癌预后的独立危险因素(HR=1.931, 95%CI:1.131~3.296;HR=2.029,95%CI:1.170~3.519)。结论 Cyclin D1高表达、pMMR及术前FIB异常的结肠癌患者预后不良。  相似文献   

19.
目的 探讨超声引导下腹横肌平面阻滞联合全身麻醉在腹腔镜结直肠癌根治术中的临床应用效果。方法 选取2017年6月至2019年6月在德阳市人民医院行腹腔镜结直肠癌根治术的100例患者为研究对象。根据随机数字表分为对照组(n=50)和观察组(n=50)。对照组给予全身麻醉,观察组在此基础上联合超声引导下腹横肌平面阻滞,比较两组血流动力学、镇痛效果及不良反应等情况。结果 观察组切皮时、癌灶切除时及术毕时的平均动脉压(mean arterial pressure,MAP)、心率(heart rate,HR)、丙泊酚用量、舒芬太尼用量、呼之睁眼时间、拔气管时间、完全苏醒时间以及术后2 h、12 h、24 h、48 h、72 h的VAS评分均低于对照组(P<0.05);术后24 h内镇痛泵按压次数、补救性镇痛次数亦低于对照组(P<0.001),但镇痛满意率高于对照组(96.0% vs 82.0%,χ2=5.005,P=0.025)。两组患者不良反应发生率比较差异无统计学意义(10.0% vs 14.0%,χ2=0.379,P=0.538)。结论 超声引导下腹横肌平面阻滞联合全麻可有效改善腹腔镜结直肠癌根治术患者镇痛效果,稳定血流动力学,减少全麻用药量,安全性较好,值得临床推广应用。  相似文献   

20.
目的 探讨细胞骨架相关蛋白4(cytoskeleton-associated protein 4,CKAP4)在肾透明细胞癌(clear cell renal cell carcinoma,ccRCC)中的表达及其临床意义。方法 收集237例ccRCC患者的癌组织和癌旁组织,采用免疫组化法检测CKAP4蛋白的表达水平,采用χ2检验比较不同CKAP4蛋白表达水平患者的临床病理特征,Kaplan-Meier法和Log-rank检验分析不同CKAP4表达水平患者总生存期(overall survival,OS)和无进展生存期(progression-free survival,PFS)的差异,Cox比例风险回归分析影响ccRCC患者术后OS和PFS的因素。结果 ccRCC组织中CKAP4蛋白的高表达率显著高于癌旁组织(54.0%vs 23.6%,χ2=46.050,P<0.001)。Fuhrman分级高、肿瘤浸润深、有淋巴结转移、远处转移以及TNM分期高的ccRCC患者癌组织中CKAP4蛋白高表达(均P<0.05)。CKAP4蛋白高表达...  相似文献   

设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号